You are Unregistered, please register to gain Full access.
Welcome to the xenoMED, an online Medical Community where Academically sound, Professionally conscious and Socially responsible Medical Students, Doctors & Health Professionals interact with each other globally.
Medicine is the only profession that incessantly tries to destroy its own existence. Howsoever you may be associated with basic and/or clinical medicine - student or professor, physician or surgeon, undergraduate or postgraduate - this is your place to share your knowledge, and learn more. Just get the message across!
You are currently viewing our communiy as a guest which gives you limited access to view most discussions and access our other features. By joining our free community you will have access to post topics, communicate privately with other members (PM), respond to polls, upload content and access many other special features. Registration is fast, simple and absolutely free so please, Join Our Medical Cummunity Today!
If you have any problems with the registration process or your account login, please contact us.
ATLANTA -- Two-year survival in newly diagnosed multiple myeloma patients improved significantly when lenalidomide (Revlimid) was given with low-dose dexamethasone rather than standard high-dose steroid therapy, according to updated results of a multicenter clinical trial.
Linear Mode
